Background Rituximab has been documented in the treatment of acute (≤ 3 days from
admission), relapsed/refractory thrombotic thrombocytopenic purpura (TTP) and given as …

Idiopathic thrombotic thrombocytopenic purpura (TTP) occurs primarily due to the formation
of autoantibody against ADAMTS13, a specific von Willebrand factor-cleaving protease …

The safety and efficacy of weekly rituximab 375 mg/m2 (× 4), given within 3 days of acute
TTP admission, with standard therapy (PEX and steroids) was evaluated. Clinical outcomes …

Objective To investigate the efficacy and safety of rituximab (RTX) as first-line treatment of
acquired thrombotic thrombocytopenic purpura (aTTP). Methods Twenty-five patients with …

The current systematic review and meta-analysis aimed to summarize the results of all
available studies to compare the efficacies of rituximab and conventional treatment for …

In 1991, a new era of effective treatment of acquired TTP began with documentation of the
efficacy of PEX, reducing mortality of acute episodes from 90% to 28%. 1 In 1998, acquired …

In acquired thrombotic thrombocytopenic purpura (TTP), the persistence of severe
ADAMTS13 deficiency (< 10%) during remission is associated with more relapse …

BACKGROUND: Between 30% and 60% of patients with thrombotic thrombocytopenic
purpura (TTP) relapse and mortality remains at 15–20%. Limited clinical data suggest that …

Acute antibody-mediated thrombotic thrombocytopenic purpura (TTP) is a thrombotic
microangiopathy with high morbidity and mortality. Rituximab is highly effective as …

Idiopathic thrombotic thrombocytopenic purpura (TTP) is a life‐threatening disease
mediated by autoantibodies directed against ADAMTS‐13. A number of small series and …